Chronic benzylpiperazine (BZP) exposure produces behavioral sensitization and cross-sensitization to methamphetamine (MA)

Drug and Alcohol Dependence

Volumn 88, Issue 2-3, 2007, Pages 204-213

  Brennan, K ^a   Johnstone, A ^a   Fitzmaurice, P ^a   Lea, R ^a   Schenk, S ^a  

^a VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

Author keywords

Benzylpiperazine; Cross sensitization; Hyperactivity; Methamphetamine; Sensitization; Stereotypy

Indexed keywords

BENZYLPIPERAZINE; METHAMPHETAMINE; PSYCHOSTIMULANT AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CROSS ALLERGY; DOSE RESPONSE; DRUG WITHDRAWAL; HYPERACTIVITY; LOCOMOTION; LONG TERM EXPOSURE; NONHUMAN; PRIORITY JOURNAL; RAT; REPEAT PROCEDURE; SENSITIZATION; STEREOTYPY;

ANIMALS; DOPAMINE; DRUG ADMINISTRATION SCHEDULE; IMMUNIZATION; MALE; METHAMPHETAMINE; MODELS, ANIMAL; MOTOR ACTIVITY; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; STEREOTYPED BEHAVIOR; TIME FACTORS;

RATTUS;

EID: 33947606509     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2006.10.016     Document Type: Article

References (95)

1. Akimoto K., Hamamura T., Kazahaya Y., Akiyama K., and Otsuki S. Enhanced extracellular dopamine level may be the fundamental neuropharmacological basis of cross-behavioral sensitization between methamphetamine and cocaine-an in vivo dialysis study in freely moving rats. Brain Res. 507 (1990) 344-346
2. Baumann M.H., Ayestas M.A., Sharpe L.G., Lewis D.B., Rice K.C., and Rothman R.B. Persistent antagonism of methamphetamine-induced dopamine release in rats pretreated with GBR12909 decanoate. J. Pharmacol. Exp. Ther. 301 (2002) 1190-1197
3. Baumann M.H., Clark R.D., Budzynski A.G., Partilla J.S., Blough B.E., and Rothman R.B. N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy'). Neuropsychopharmacology 30 (2005) 550-560
4. Bevins R.A., and Peterson J.L. Individual differences in rats' reactivity to novelty and the unconditioned and conditioned locomotor effects of methamphetamine. Pharmacol. Biochem. Behav. 79 (2004) 65-74
5. Bonate P.L., Swann A., and Silverman P.B. Behavioral sensitization to cocaine in the absence of altered brain cocaine levels. Pharmacol. Biochem. Behav. 57 (1997) 665-669
6. Bordi F., and Meller E. Enhanced behavioral stereotypies elicited by intrastriatal injection D1 and D2 dopamine agonists in intact rats. Brain Res. 504 (1989) 276-283
7. Camp D.M., Browman K.E., and Robinson T.E. The effects of methamphetamine and cocaine on motor behavior and extracellular dopamine in the ventral striatum of Lewis versus Fischer 344 rats. Brain Res. 668 (1994) 180-193
8. Campbell H., Cline W., Evans M., Lloyd J., and Peck A.W. Comparison of the effects of dexamphetamine and 1-benzylpiperazine in former addicts. Eur. J. Clin. Pharmacol. 6 (1973) 170-176
9. Castall B., Marsden C.D., Naylor R.J., and Pycock C.J. Stereotyped behaviour patterns and hyperactivity induced by amphetamine and apomorphine after discrete 6-hydroxydopamine lesions of extrapyramidal and mesolimbic nuclei. Brain Res. 123 (1977) 89-111
10. Chang L., Ernst T., Speck O., Patel H., DeSilva M., Leonido-Yee M., and Miller E.N. Perfusion MRI and computerized cognitive test abnormalities in abstinent methamphetamine users. Psychiatry Res. 114 (2002) 65-79
11. Chiu C.T., Ma T., and Ho I.K. Attenuation of methamphetamine-induced behavioral sensitization in mice by systemic administration of naltrexone. Brain Res. Bull. 67 (2005) 100-109
12. Cho A.K., Melega W.P., Kuczenski R., Segal D.S., and Schmitz D.A. Caudate-putamen dopamine and stereotypy response profiles after intravenous and subcutaneous amphetamine. Synapse 31 (1999) 125-133
13. Conti L.H., Segal D.S., and Kuczenski R. Maintenance of amphetamine-induced stereotypy and locomotion requires ongoing dopamine receptor activation. Psychopharmacology (Berl.) 130 (1997) 183-188
14. Costall B., Naylor R.J., and Neumeyer J.L. Differences in the nature of the stereotyped behaviour induced by aporphine derivatives in the rat and in their actions in extrapyramidal and mesolimbic brain areas. Eur. J. Pharmacol. 31 (1975) 1-16
15. Cuddy M.L. Common drugs of abuse-Part II. J. Pract. Nurs. 54 5-8 (2004) 25-31 quiz 17-29
16. Cunningham C.L., and Noble D. Methamphetamine-induced conditioned place preference or aversion depending on dose and presence of drug. Ann. N. Y. Acad. Sci. 654 (1992) 431-433
17. Daniela E., Brennan K., Gittings D., Hely L., and Schenk S. Effect of SCH 23390 on (+/-)-3,4-methylenedioxymethamphetamine hyperactivity and self-administration in rats. Pharmacol. Biochem. Behav. 77 (2004) 745-750
18. Davidson C., Lee T.H., and Ellinwood E.H. Acute and chronic continuous methamphetamine have different long-term behavioral and neurochemical consequences. Neurochem. Int. 46 (2005) 189-203
19. Di Chiara G., and Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 5274-5278
20. Dietze S., and Kuschinsky K. Effect of conditioning with d-amphetamine on the extracellular concentration of dopamine and its metabolites in the striatum of behaving rats. Naunyn Schmiedebergs Arch. Pharmacol. 350 (1994) 22-27
21. Elmer G.I., Gorelick D.A., Goldberg S.R., and Rothman R.B. Acute sensitivity vs. context-specific sensitization to cocaine as a function of genotype. Pharmacol. Biochem. Behav. 53 (1996) 623-628
22. Fantegrossi W.E., Winger G., Woods J.H., Woolverton W.L., and Coop A. Reinforcing and discriminative stimulus effects of 1-benzylpiperazine and trifluoromethylphenylpiperazine in rhesus monkeys. Drug Alcohol Depend. 77 (2005) 161-168
23. Fletcher P.J., Robinson S.R., and Slippoy D.L. Pre-exposure to (+/-)3,4-methylenedioxy-methamphetamine (MDMA) facilitates acquisition of intravenous cocaine self-administration in rats. Neuropsychopharmacology 25 (2001) 195-203
24. Fujio M., Nakagawa T., Suzuki Y., Satoh M., and Kaneko S. Facilitative effect of a glutamate transporter inhibitor (2S,3S)-3-{3-[4-(trifluoromethyl)benzoylamino]benzyloxy}aspartate on the expression of methamphetamine-induced behavioral sensitization in rats. J. Pharmacol. Sci. 99 (2005) 415-418
25. Fujiwara Y., Kazahaya Y., Nakashima M., Sato M., and Otsuki S. Behavioral sensitization to methamphetamine in the rat: an ontogenic study. Psychopharmacology (Berl.) 91 (1987) 316-319
26. Gaiardi M., Bartoletti M., Bacchi A., Gubellini C., Costa M., and Babbini M. Role of repeated exposure to morphine in determining its affective properties: place and taste conditioning studies in rats. Psychopharmacology (Berl.) 103 (1991) 183-186
27. Gibson D.R., Leamon M.H., and Flynn N. Epidemiology and public health Consequences of methamphetamine use in California's Central Valley. J. Psychoactive Drugs 34 (2002) 313-319
28. Giorgi O., Piras G., Lecca D., and Corda M.G. Differential activation of dopamine release in the nucleus accumbens core and shell after acute or repeated amphetamine injections: a comparative study in the Roman high- and low-avoidance rat lines. Neuroscience 135 (2005) 987-998
29. Golembiowska K., and Zylewska A. Effect of adenosine kinase, adenosine deaminase and transport inhibitors on striatal dopamine and stereotypy after methamphetamine administration. Neuropharmacology 39 (2000) 2124-2132
30. Hamamura T., Akiyama K., Akimoto K., Kashihara K., Okumura K., Ujike H., and Otsuki S. Co-administration of either a selective D1 or D2 dopamine antagonist with methamphetamine prevents methamphetamine-induced behavioral sensitization and neurochemical change, studied by in vivo intracerebral dialysis. Brain Res. 546 (1991) 40-46
31. Hirabayashi M., Okada S., and Tadokoro S. Comparison of sensitization to ambulation-increasing effects of cocaine and methamphetamine after repeated administration in mice. J. Pharm. Pharmacol. 43 (1991) 827-830
32. Horger B.A., Shelton K., and Schenk S. Preexposure sensitizes rats to the rewarding effects of cocaine. Pharmacol. Biochem. Behav. 37 (1990) 707-711
33. Horger B.A., Giles M.K., and Schenk S. Preexposure to amphetamine and nicotine predisposes rats to self-administer a low dose of cocaine. Psychopharmacology (Berl.) 107 (1992) 271-276
34. Hyman S.E. Addiction to cocaine and amphetamine. Neuron 16 (1996) 901-904
35. Ito K., Abekawa T., and Koyama T. Valproate blocks high-dose methamphetamine-induced behavioral cross-sensitization to locomotion-inducing effect of dizocilpine (MK-801), but not methamphetamine. Psychopharmacology (Berl.) 186 (2006) 525-533
36. Ito K., Ohmori T., Abekawa T., and Koyama T. Clonazepam prevents the development of sensitization to methamphetamine. Pharmacol. Biochem. Behav. 58 (1997) 875-879
37. Itoh K., Fukumori R., and Suzuki Y. Effect of methamphetamine on the locomotor activity in the 6OHDA dorsal hippocampus lesioned rat. Life Sci. 34 (1984) 827-833
38. Itzhak Y. Modulation of cocaine- and methamphetamine-induced behavioral sensitization by inhibition of brain nitric oxide synthase. J. Pharmacol. Exp. Ther. 282 (1997) 521-527
39. Johanson C.E., Balster R.L., and Bonese K. Self-administration of psychomotor stimulant drugs: the effects of unlimited access. Pharmacol. Biochem. Behav. 4 (1976) 45-51
40. Kalivas P.W., Duffy P., and White S.R. MDMA elicits behavioral and neurochemical sensitization in rats. Neuropsychopharmacology 18 (1998) 469-479
41. Kawakami Y., Suemaru K., Araki H., Kawasaki H., Gomita Y., and Tanizaki Y. Repeated mazindol and methamphetamine administration produces cross-sensitization to stereotyped behavior induced by these agents in rats. Acta Med. Okayama 52 (1998) 169-171
42. Kazahaya Y., Akimoto K., and Otsuki S. Subchronic methamphetamine treatment enhances methamphetamine- or cocaine-induced dopamine efflux in vivo. Biol. Psychiatry 25 (1989) 903-912
43. Kehne J.H., Ketteler H.J., McCloskey T.C., Sullivan C.K., Dudley M.W., and Schmidt C.J. Effects of the selective 5-HT2A receptor antagonist MDL 100,907 on MDMA-induced locomotor stimulation in rats. Neuropsychopharmacology 15 (1996) 116-124
44. Kelly P.H., and Iversen S.D. Selective 6OHDA-induced destruction of mesolimbic dopamine neurons: abolition of psychostimulant-induced locomotor activity in rats. Eur. J. Pharmacol. 40 (1976) 45-56
45. Kitaichi K., Morishita Y., Doi Y., Ueyama J., Matsushima M., Zhao Y.L., Takagi K., and Hasegawa T. Increased plasma concentration and brain penetration of methamphetamine in behaviorally sensitized rats. Eur. J. Pharmacol. 464 (2003) 39-48
46. Kitanaka N., Kitanaka J., and Takemura M. Behavioral sensitization and alteration in monoamine metabolism in mice after single versus repeated methamphetamine administration. Eur. J. Pharmacol. 474 (2003) 63-70
47. Koob G.F., Stinus L., and Le Moal M. Hyperactivity and hypoactivity produced by lesions to the mesolimbic dopamine system. Behav. Brain Res. 3 (1981) 341-359
48. Kuczenski R., and Segal D.S. An escalating dose/multiple high-dose binge pattern of amphetamine administration results in differential changes in the extracellular dopamine response profiles in caudate-putamen and nucleus accumbens. J. Neurosci. 17 (1997) 4441-4447
49. Kuribara H. Does nicotine modify the psychotoxic effect of methamphetamine? Assessment in terms of locomotor sensitization in mice. J. Toxicol. Sci. 24 (1999) 55-62
50. Le A.D., Tomkins D., Higgins G., Quan B., and Sellers E.M. Effects of 5-HT3, D1 and D2 receptor antagonists on ethanol- and cocaine-induced locomotion. Pharmacol. Biochem. Behav. 57 (1997) 325-332
51. Lett B.T. Repeated exposures intensify rather than diminish the rewarding effects of amphetamine, morphine, and cocaine. Psychopharmacology (Berl.) 98 (1989) 357-362
52. Li J.X., Han R., Deng Y.P., Chen S.Q., and Liang J.H. Different effects of valproate on methamphetamine- and cocaine-induced behavioral sensitization in mice. Behav. Brain Res. 161 (2005) 125-132
53. Lorrain D.S., Arnold G.M., and Vezina P. Previous exposure to amphetamine increases incentive to obtain the drug: long-lasting effects revealed by the progressive ratio schedule. Behav. Brain Res. 107 (2000) 9-19
54. Maurer H.H., Kraemer T., Springer D., and Staack R.F. Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis. Ther. Drug Monit. 26 (2004) 127-131
55. McCann U.D., and Ricaurte G.A. Amphetamine neurotoxicity: accomplishments and remaining challenges. Neurosci. Biobehav. Rev. 27 (2004) 821-826
56. Mendrek A., Blaha C.D., and Phillips A.G. Pre-exposure of rats to amphetamine sensitizes self-administration of this drug under a progressive ratio schedule. Psychopharmacology (Berl.) 135 (1998) 416-422
57. Meririnne E., Kajos M., Kankaanpaa A., and Seppala T. Rewarding properties of 1-benzylpiperazine, a new drug of abuse, in rats. Basic Clin. Pharmacol. Toxicol. 98 (2006) 346-350
58. Monterosso J.R., Aron A.R., Cordova X., Xu J., and London E.D. Deficits in response inhibition associated with chronic methamphetamine abuse. Drug Alcohol Depend. 79 (2005) 273-277
59. Murray J.B. Psychophysiological aspects of amphetamine-methamphetamine abuse. J. Psychol. 132 (1998) 227-237
60. Nakagawa N., Hishinuma T., Nakamura H., Yamazaki T., Tsukamoto H., Hiratsuka M., Ido T., Mizugaki M., Terasaki T., and Goto J. Brain and heart specific alteration of methamphetamine (MAP) distribution in MAP-sensitized rat. Biol. Pharm. Bull. 26 (2003) 506-509
61. Ohmori T., Abekawa T., and Koyama T. Environment modifies the expression of behavioral sensitization produced by methamphetamine: behavioral and neurochemical studies. Behav. Pharmacol. 6 (1995) 133-142
62. O'Neill M.F., and Shaw G. Comparison of dopamine receptor antagonists on hyperlocomotion induced by cocaine, amphetamine, MK-801 and the dopamine D1 agonist C-APB in mice. Psychopharmacology (Berl.) 145 (1999) 237-250
63. O'Neill M.F., Heron-Maxwell C.L., and Shaw G. 5-HT2 receptor antagonism reduces hyperactivity induced by amphetamine, cocaine, and MK-801 but not D1 agonist C-APB. Pharmacol. Biochem. Behav. 63 (1999) 237-243
64. Pierre P.J., and Vezina P. Predisposition to self-administer amphetamine: the contribution of response to novelty and prior exposure to the drug. Psychopharmacology (Berl.) 129 (1997) 277-284
65. Pierre P.J., and Vezina P. D1 dopamine receptor blockade prevents the facilitation of amphetamine self-administration induced by prior exposure to the drug. Psychopharmacology (Berl.) 138 (1998) 159-166
66. Puopolo M., Hochstetler S.E., Gustincich S., Wightman R.M., and Raviola E. Extrasynaptic release of dopamine in a retinal neuron: activity dependence and transmitter modulation. Neuron 30 (2001) 211-225
67. Roberts D.C., Zis A.P., and Fibiger H.C. Ascending catecholamine pathways and amphetamine-induced locomotor activity: importance of dopamine and apparent non-involvement of norepinephrine. Brain Res. 93 (1975) 441-454
68. Robinson T.E., and Becker J.B. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res. 396 (1986) 157-198
69. Robinson T.E., and Berridge K.C. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res. Brain Res. Rev. 18 (1993) 247-291
70. Robinson T.E., and Kolb B. Alterations in the morphology of dendrites and dendritic spines in the nucleus accumbens and prefrontal cortex following repeated treatment with amphetamine or cocaine. Eur. J. Neurosci. 11 (1999) 1598-1604
71. Robinson T.E., and Berridge K.C. Incentive-sensitization and addiction. Addiction 96 (2001) 103-114
72. Scheel-Kruger J. Dopamine-GABA interactions: evidence that GABA transmits, modulates and mediates dopaminergic functions in the basal ganglia and the limbic system. Acta Neurol. Scand. Suppl. 107 (1986) 1-54
73. Schenk S., and Partridge B. Sensitization and tolerance in psychostimulant self-administration. Pharmacol. Biochem. Behav. 57 (1997) 543-550
74. Schenk S., and Izenwasser S. Pretreatment with methylphenidate sensitizes rats to the reinforcing effects of cocaine. Pharmacol. Biochem. Behav. 72 (2002) 651-657
75. Schindler C.W., and Carmona G.N. Effects of dopamine agonists and antagonists on locomotor activity in male and female rats. Pharmacol. Biochem. Behav. 72 (2002) 857-863
76. Sekine Y., Minabe Y., Ouchi Y., Takei N., Iyo M., Nakamura K., Suzuki K., Tsukada H., Okada H., Yoshikawa E., Futatsubashi M., and Mori N. Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms. Am. J. Psychiatry 160 (2003) 1699-1701
77. Sessions G.R., Meyerhoff J.L., Kant G.J., and Koob G.F. Effects of lesions of the ventral medial tegmentum on locomotor activity, biogenic amines and responses to amphetamine in rats. Pharmacol. Biochem. Behav. 12 (1980) 603-608
78. Sharp T., Zetterstrom T., Ljungberg T., and Ungerstedt U. A direct comparison of amphetamine-induced behaviours and regional brain dopamine release in the rat using intracerebral dialysis. Brain Res. 401 (1987) 322-330
79. Shepard J.D., Chuang D.T., Shaham Y., and Morales M. Effect of methamphetamine self-administration on tyrosine hydroxylase and dopamine transporter levels in mesolimbic and nigrostriatal dopamine pathways of the rat. Psychopharmacology (Berl.) 185 (2006) 505-513
80. Shippenberg T.S., and Heidbreder C. Sensitization to the conditioned rewarding effects of cocaine: pharmacological and temporal characteristics. J. Pharmacol. Exp. Ther. 273 (1995) 808-815
81. Shippenberg T.S., Heidbreder C., and Lefevour A. Sensitization to the conditioned rewarding effects of morphine: pharmacology and temporal characteristics. Eur. J. Pharmacol. 299 (1996) 33-39
82. Shuto T., Kuroiwa M., Hamamura M., Yabuuchi K., Shimazoe T., Watanabe S., Nishi A., and Yamamoto T. Reversal of methamphetamine-induced behavioral sensitization by repeated administration of a dopamine D(1) receptor agonist. Neuropharmacology 50 (2006) 991-997
83. Suzuki H., Shishido T., Watanabe Y., Abe H., Shiragata M., Honda K., Horikoshi R., and Niwa S. Changes of behavior and monoamine metabolites in the rat brain after repeated methamphetamine administration: effects of duration of repeated administration. Prog. Neuropsychopharmacol. Biol. Psychiatry 21 (1997) 359-369
84. Suzuki T., Shiozaki Y., Masukawa Y., and Misawa M. 5-HT3 receptor antagonists block cocaine- and methamphetamine-induced place preference. Yakubutsu Seishin Kodo 12 (1992) 33-38
85. Swerdlow N.R., Vaccarino F.J., Amalric M., and Koob G.F. The neural substrates for the motor-activating properties of psychostimulants: a review of recent findings. Pharmacol. Biochem. Behav. 25 (1986) 233-248
86. UNODC, 2006. United Nations Office of Drugs and Crime: World Drug Report. http://wwwunodcorg/unodc/world_drug_reporthtml (accessed 19/09/06).
87. Valadez A., and Schenk S. Persistence of the ability of amphetamine preexposure to facilitate acquisition of cocaine self-administration. Pharmacol. Biochem. Behav. 47 (1994) 203-205
88. Volkow N.D., Chang L., Wang G.J., Fowler J.S., Leonido-Yee M., Franceschi D., Sedler M.J., Gatley S.J., Hitzemann R., Ding Y.S., Logan J., Wong C., and Miller E.N. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am. J. Psychiatry 158 (2001) 377-382
89. Wikstrom M., Holmgren P., and Ahlner J. A2 (N-benzylpiperazine) a new drug of abuse in Sweden. J. Anal. Toxicol. 28 (2004) 67-70
90. Wilkins C., Girling M., Sweetsur P., Huckle T., and Huakau J. National Household Survey. Legal Party Pill Use in New Zealand: Prevalence of Use, Availability Health Harms and 'gateway effects' of Benzylpiperazine (BZP) and Trifluorophenylmethylpiperazine (TFMPP) (2006). http://www.shore.ac.nz/projects/Legal%20party%20pills%20in%20New%20Zealand%20report.pdf (accessed 19/09/06)
91. Woolverton W.L., Goldberg L.I., and Ginos J.Z. Intravenous self-administration of dopamine receptor agonists by rhesus monkeys. J. Pharmacol. Exp. Ther. 230 (1984) 678-683
92. Yamamoto T., Takano R., Egashira T., and Yamanaka Y. Reversible inhibition of aromatic hydroxylation of methamphetamine in rat liver microsomal preparations pretreated with methamphetamine. Biochem. Pharmacol. 37 (1988) 1433-1437
93. Yokel R.A., and Pickens R. Self-administration of optical isomers of amphetamine and methylamphetamine by rats. J. Pharmacol. Exp. Ther. 187 (1973) 27-33
94. Yoshida H., Ohno M., and Watanabe S. Roles of dopamine D1 receptors in striatal fos protein induction associated with methamphetamine behavioral sensitization in rats. Brain Res. Bull. 38 (1995) 393-397
95. Yui K., Ishiguro T., Goto K., Ikemoto S., and Kamata Y. Spontaneous recurrence of methampetamine psychosis: increased sensitivity to stress associated with noradrenergic hyperactivity and dopaminergic change. Eur. Arch. Psychiatry Clin. Neurosci. 249 (1999) 103-111